Impact of the changes in chronic myeloid leukemia classification proposed by the 2022 World Health Organization: a single-center Brazilian study

INTRODUCTION: The latest edition of the 2022 World Health Organization (WHO) classification for chronic myeloid leukemia omitted the definition of accelerated phase. METHODS: This study evaluated the impact of using the updated classification in chronic myeloid leukemia patients treated upfront with imatinib by analyzing the outcomes of 139 newly diagnosed patients, previously classified according to the 2017 WHO criteria. RESULTS: Using the updated WHO Classification, eight (6%) cases previously characterized as accelerated phase were classified as chronic phase. Overall survival (OS) was comparable under both the 2017 and 2022 WHO classifications. For patients in the chronic phase, OS was 86% at 60 months and 70% at 96 months (compared to 85% and 69% respectively under 2022 criteria). Conversely, outcomes were significantly poorer for advanced stages, with 0% survival for the accelerated phase and 25% for blast crisis (p-value <0.0001). Progression-free survival was 85% and 69% for the chronic phase and 25% for blast crisis (p-value <0.0001) by the 2017 WHO classification and 83% and 68% for chronic phase and 25% for blast crisis (p-value <0.0001) according to the 2022 WHO classification. Independent predictors of overall survival included basophil count, 2022 WHO classification, and age at tyrosine kinase inhibitor therapy initiation. For progression-free survival, the 2022 WHO classification (specifically blast crisis) and age at diagnosis were identified as significant factors. CONCLUSIONS: Age, elevated basophil count, and advanced disease at diagnosis remain associated with worse outcomes. The omission of the accelerated phase did not significantly affect the prognosis in this cohort. However, it may affect the treatment of individual patients in Brazil, since higher doses of tyrosine kinase inhibitors are indicated for those who meet the criteria for the previous accelerated phase definition.

Authors

Institutions

Publication Details

Journal
Hematology Transfusion and Cell Therapy
Published
2026-05-16
DOI
https://doi.org/10.1016/j.htct.2026.106470
Primary Topic
Chronic Myeloid Leukemia Treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Impact of the changes in chronic myeloid leukemia classification proposed by the 2022 World Health Organization: a single-center Brazilian study

K Pagnano, Guilherme Brasil Duffles Amarante, EC Miranda, Gislaine Duarte et al.
Hematology Transfusion and Cell Therapy
Chronic Myeloid Leukemia Treatments
article

Impact of the changes in chronic myeloid leukemia classification proposed by the 2022 World Health Organization: a single-center Brazilian study

K Pagnano, Guilherme Brasil Duffles Amarante, EC Miranda, Gislaine Duarte, G Santos, Estela Gasparotto Emiliano, Carmino Antônio De Souza
article en

Abstract

INTRODUCTION: The latest edition of the 2022 World Health Organization (WHO) classification for chronic myeloid leukemia omitted the definition of accelerated phase. METHODS: This study evaluated the impact of using the updated classification in chronic myeloid leukemia patients treated upfront with imatinib by analyzing the outcomes of 139 newly diagnosed patients, previously classified according to the 2017 WHO criteria. RESULTS: Using the updated WHO Classification, eight (6%) cases previously characterized as accelerated phase were classified as chronic phase. Overall survival (OS) was comparable under both the 2017 and 2022 WHO classifications. For patients in the chronic phase, OS was 86% at 60 months and 70% at 96 months (compared to 85% and 69% respectively under 2022 criteria). Conversely, outcomes were significantly poorer for advanced stages, with 0% survival for the accelerated phase and 25% for blast crisis (p-value <0.0001). Progression-free survival was 85% and 69% for the chronic phase and 25% for blast crisis (p-value <0.0001) by the 2017 WHO classification and 83% and 68% for chronic phase and 25% for blast crisis (p-value <0.0001) according to the 2022 WHO classification. Independent predictors of overall survival included basophil count, 2022 WHO classification, and age at tyrosine kinase inhibitor therapy initiation. For progression-free survival, the 2022 WHO classification (specifically blast crisis) and age at diagnosis were identified as significant factors. CONCLUSIONS: Age, elevated basophil count, and advanced disease at diagnosis remain associated with worse outcomes. The omission of the accelerated phase did not significantly affect the prognosis in this cohort. However, it may affect the treatment of individual patients in Brazil, since higher doses of tyrosine kinase inhibitors are indicated for those who meet the criteria for the previous accelerated phase definition.

Hematology Transfusion and Cell TherapyVol. 48(3)
Universidade Estadual de Campinas (UNICAMP) (BR)
Conselho Nacional de Desenvolvimento Científico e Tecnológico
No poverty
Openalex Percentile: Top 5%
Chronic Myeloid Leukemia Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.